Neuphoria Therapeutics Inc. (NEUP)

NASDAQ: NEUP · USD

$3.38

-0.01 (-0.3%)· Recorded snapshot

Market cap	18.3M
Revenue (ttm)	1.2M
Net income (ttm)	-13.5M
EPS (ttm)	-$3.06
Shares out	5.4M
Volume	15,314

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.2M
Net income (ttm): -13.5M
EPS (ttm): -$3.06
Market cap: 18.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	보유

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-61.7

P25 n/aP50 n/aP75 n/a

ROIC-25.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NEUP indicators

Market & fundamental data

Available fields

178

Groups with data

Currency

USD

Showing 178 of 178 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001191070
Company name	Neuphoria Therapeutics Inc.
Country	United States
Country code	US
CUSIP number	64136E102
Earnings date	2026-11-13
Earnings time	bmo
Employees	1
Employees change	-7
Employees growth	-87.5%
Enterprise value	$-1.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	June
Founded	1996
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US64136E1029
Last 10-K release date	2026-09-18
Last earnings date	2026-09-18
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$18.3M
Market cap category	Nano-Cap
Next earnings date	2026-11-13
Options	No
Price	$3.38
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	NEUP
U.S. state	Massachusetts
Website	https://www.neuphoriatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-90.54%
FCF / EV yield	830.87%
FCF yield	-67.34%
P/B ratio	0.75x
P/S ratio	15.62x
Price / tangible book value	1.08x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-767.32%
Pretax margin	-1,157.51%
Profit per employee	$-13.5M
Revenue per employee	$1.2M
ROA	-19.65%
ROA (5Y)	-23.38%
ROCE	-32.23%
ROE	-61.7%
ROE (5Y)	-51.04%
ROIC	-25.72%
SBC / revenue	29.94%
Tax / revenue	-11.85%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Gross profit growth	-92.5%
Net income growth quarters	1
Net income growth years	0
Revenue growth	-92.5%
Revenue growth 10Y	-22.12%
Revenue growth 5Y	11.03%
Revenue growth quarters	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$662,955
EBIT	$-9M
EBITDA	$-8.3M
EPS	$-3.06
FCF per share	$-2.28
Financing cash flow	$17.9M
Free cash flow	$-12.4M
Free cash flow minus SBC	$-12.7M
Gross profit	$1.2M
Income taxes	$-139,173
Net cash flow	$5.6M
Net income	$-13.5M
Operating cash flow minus SBC	$-12.7M
Operating income	$-9M
Revenue	$1.2M
Stock-based compensation	$351,600

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-6.24
Book value per share	$4.55
Debt / equity	0
Goodwill	$3.5M
Long-term assets	$7.6M
Long-term liabilities	$3.4M
Net cash (debt)	$19.8M
Net cash / market cap	108.1%
Net cash growth	41.03%
Net debt / equity	-0.81
Piotroski F-Score	2
Shareholders' equity	$24.6M
Tangible book value	$17M
Tangible book value per share	$3.13
Total assets	$28.7M
Total cash	$19.9M
Total debt	$34,345
Total liabilities	$4.1M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.04
Current assets	$21.1M
Current liabilities	$756,581
Current ratio	27.85
Net working capital	$480,967
Quick ratio	27.33
Working capital	$20.3M
Working capital turnover	0.08

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-170.86%
Dividend yield	0%
Shareholder yield	-170.86%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$4.14
1D price change	-0.29%
1M price change	-7.19%
1M total return	-7.19%
1W price change	-0.07%
1W total return	-0.07%
1Y price change	-25.22%
1Y return CAGR	-25.24%
1Y total return	-25.22%
20-day SMA	$3.39
200-day SMA	$4.17
3M price change	-12.01%
3M total return	-12.01%
50-day SMA	$3.61
50-day SMA vs 200-day SMA	50under200
52-week high	$5.53
52-week high date	2026-05-26
52-week low	$3.19
52-week low date	2026-07-01
6M price change	-34.22%
6M total return	-34.22%
All-time high	$21.40
All-time high date	2025-10-07
All-time low	$2.90
All-time low date	2025-01-02
Average true range (ATR)	$0.12
Average volume	22.6K
Beta (1Y)	0.73
Beta (2Y)	0.13
Change from 52-week high	-38.88%
Change from 52-week low	5.96%
Change from all-time high	-84.17%
Change from all-time low	16.81%
Change from open	-0.59%
Day's gap	0.29%
Dollar volume	$51,761
High price	$3.46
Low price	$3.33
Monthly RSI	48.46
Open price	$3.40
Position in 52-week range	39.06%
Previous close	$3.39
Price vs 150-day SMA	-18.2%
Price vs 20-day SMA	-0.1%
Price vs 200-day SMA	-18.82%
Price vs 50-day SMA	-6.19%
Relative volume	0.68
RSI	42.42
Sharpe ratio	-0.34
Sortino ratio	-0.39
Volume	15.3K
Weekly RSI	39.09
YTD price change	-12.69%
YTD total return	-12.69%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	5.4M
Float percentage	99.27%
Shares change (QoQ)	-0.07%
Shares change (YoY)	170.86%
Shares held by insiders	0.73%
Shares held by institutions	41.74%
Shares outstanding	5.4M
Short % of float	0.12%
Short % of shares	0.12%
Short ratio	1.1 days

Deeper analysis on NEUP

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NEUP report

Is a complete NEUP research report available?

No complete published report is available for Neuphoria Therapeutics Inc. (NEUP) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Neuphoria Therapeutics Inc. (NEUP)

Price

Financial snapshot

Fair-value bridge

Latest news · NEUP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NEUP indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NEUP

Frequently asked questions